Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Borson R, Harker G, Reeves J, Beck T, Hager S, Horvath W, Jones M, Tillinghast G, Arrowsmith E, Harrer G, Kudrik FJ, Malamud SC, Bromund J, Zeigler H, Tai DF, Kornberg LJ, Obasaju C, Orlando M, Yardley DA.
Borson R, et al. Among authors: malamud sc.
Clin Breast Cancer. 2012 Oct;12(5):322-30. doi: 10.1016/j.clbc.2012.07.004.
Clin Breast Cancer. 2012.
PMID: 23040000
Clinical Trial.